U
RGLS

UBS’s Regulus Therapeutics RGLS Stock Holding History

UBS’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$55K Sell
67
-14
-17% -$11.8K ﹤0.01% 6711
2014
Q2 		$78K Buy
81
+14
+21% +$12K ﹤0.01% 6258
2014
Q1 		$72K Buy
67
+27
+68% +$29.9K ﹤0.01% 6383
2013
Q4 		$36K Sell
40
-33
-45% -$28.4K ﹤0.01% 7395
2013
Q3 		$83K Buy
73
+11
+18% +$13K ﹤0.01% 6231
2013
Q2 		$74K Buy
+62
New +$58.9K ﹤0.01% 6265

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return

UBS's RGLS Position: Q3 2014 in Review

UBS reduced its Regulus Therapeutics (RGLS) stake by 17% in Q3 2014, selling an estimated $11.8K and leaving 67 shares worth $55K. The position accounts for ﹤0.01% of the portfolio, ranked #6711.

UBS first reported a position in RGLS in Q2 2013 and has held it in 6 quarters since. The position peaked at $83K in Q3 2013. 49 funds tracked by Wall St. Rank hold RGLS as of Q3 2014.

  • UBS held 67 shares of Regulus Therapeutics worth $55K as of Q3 2014.
  • UBS sold 14 Regulus Therapeutics shares in Q3 2014, an estimated $11.8K.
  • Regulus Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #6711 holding.
  • UBS first reported a position in Regulus Therapeutics in Q2 2013 and has held it in 6 quarters since.
  • UBS's Regulus Therapeutics position peaked at $83K in Q3 2013.
  • 49 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.